Stockreport

AbCellera Biologics Eyes Integrated Biotech Shift; ABCL635 Phase II Data Due in Q3 at Forum [Yahoo! Finance]

AbCellera Biologics Inc. - Common Shares  (ABCL) 
PDF AbCellera Biologics (NASDAQ:ABCL) is working to evolve from a technology-enabled drug discovery partner into what the company described as an integrated biotech with in [Read more]